TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03497871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMan system
Description: The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
Study: NCT04361422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin Only Product in Oral Dose Form
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Isotretinoin Only Product in Oral Dose Form
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin Only Product in Oral Dose Form
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
Study: NCT01209403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-infusion
Description: Continuous iv infusion of glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-insulin infusion
Description: Continuous iv infusion of glucose and shortlasting
Study: NCT03003442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® Energy 3RDA
Description: Multivitamin/mineral containing co-Q10

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04504110

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
Description: Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
Study: NCT03200353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: system NATROX (device name)
Description: system NATROX (device name) application on the wounds of lower limbs
Study: NCT03988153

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic Milk Formula
Description: Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Milk Formula
Description: Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
Study: NCT01575171

Intervention type: BEHAVIORAL
Intervention: Nudge
Description: Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines.
Study: NCT00642226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grid Laser
Description: ETDRS Grid Laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy and 20 mg triamcinolone
Description: Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
Study: NCT01023594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic stent
Description: Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic stent
Description: Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
Study: NCT00916552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
Study: NCT01171157

Intervention type: OTHER
Intervention: Routine sample collection
Description: Collection of routine nasal/throat swab samples
Study: NCT03847961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion with cytokine adsorption column (CA330)
Description: Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
Study: NCT02616783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC
Description: 200 mg capsule administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third agent
Description: Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study: NCT03663296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway Ex App
Description: 30 minutes of self-directed learning and practice using the mobile application
Study: NCT01307813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suturing System
Description: Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model
Study: NCT01491425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS//LT-CAGE® Device
Description: LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone//LT-CAGE® Device
Description: LT-CAGE® device with autogenous bone taken from the iliac crest.
Study: NCT01634646

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lyzme5
Description: Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day.
Study: NCT04630223

Intervention type: DIAGNOSTIC_TEST
Intervention: endocan in umbilical cord blood
Description: After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: endocan in umbilical cord blood
Description: After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
Study: NCT02709148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: DBS
Study: NCT00955799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment period of 29 weeks placebo
Study: NCT02664077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
Study: NCT03686553

Intervention type: OTHER
Intervention: laboratory-based data collection
Description: laboratory-based surveillance of SSI

Intervention type: OTHER
Intervention: laboratory-based data collection
Description: laboratory-based surveillance of SSI
Study: NCT03564470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
Study: NCT01309321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Handwashing Promotion
Description: Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Health Promotion
Description: Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
Study: NCT00072410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hu3S193
Description: Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hu3S193
Description: Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-hu3S193
Description: Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-hu3S193
Description: Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
Study: NCT01706367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Description: 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine +adjuvant
Description: 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Description: 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine +adjuvant
Description: 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Description: 0.5 mL IM injection
Study: NCT02509832

Intervention type: DEVICE
Group type: OTHER
Intervention: PCI only
Description: Standard of Care for PCI
Study: NCT01205854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
Study: NCT02564380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03223831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered pyloro-duodenal stent
Description: The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 \& 12cm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered pyloro-duodenal stents
Description: The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
Study: NCT03950700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution 0.9% (Baxter laboratories).
Study: NCT01706367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine +adjuvant
Description: 0.5 mL IM injection
Study: NCT04355377

Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study: NCT01291940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Moisturizer
Description: Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult Moisturizer
Description: Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
Study: NCT00384189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder
Study: NCT00696943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-ML-10)
Description: \[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
Study: NCT02106962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid 5% with bacitracin
Description: Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid 25% with bacitracin
Description: Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
Study: NCT01552226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Preperitoneal Analgesia
Description: Preperitoneal catheter placed at the completion of surgery in the standard fashion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Analgesia
Description: Epidural catheter placed prior to the operation in the standard fashion.
Study: NCT00248651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
Study: NCT00765856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications
Study: NCT03012932

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV self-sampling
Description: All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
Study: NCT01365130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: jevtana
Description: Cabazitaxel 25mg/m2, IV every 21 days until progression
Study: NCT03065647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expedited Transport With Mechanical CPR
Description: Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
Study: NCT04110353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: Conservative dressings
Description: Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.